-transparent.png){kind=logo}
Methamphetamine (5 mg/kg) administered 30 min prior to each injection with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) (3 x 30 mg/kg, at 24 h intervals) prevents the reduction of striatal levels of dopamine and its metabolites in C57BL mice. Methamphetamine and amphetamine inhibit the uptake of 1-methyl-4-phenylpyridinium (MPP+) by striatal synaptosomes of rats. A 30-min post-treatment with methamphetamine or amphetamine also prevents the MPTP-induced dopamine depletion, suggesting that their protective effect is related to the blockade of MPP+ uptake into dopaminergic neurons. Since amphetamine and methamphetamine are themselves neurotoxins at higher doses, this work demonstrated the protection against the actions of one neurotoxin by the administration of another.
I Sziráki, and
V Kardos, and
M Patthy, and
M Pátfalusi, and
G Budai
September 2007,
The European journal of neuroscience,
I Sziráki, and
V Kardos, and
M Patthy, and
M Pátfalusi, and
G Budai
July 1999,
Movement disorders : official journal of the Movement Disorder Society,
I Sziráki, and
V Kardos, and
M Patthy, and
M Pátfalusi, and
G Budai
June 2010,
Brain research,
I Sziráki, and
V Kardos, and
M Patthy, and
M Pátfalusi, and
G Budai
July 2009,
Cellular and molecular neurobiology,
I Sziráki, and
V Kardos, and
M Patthy, and
M Pátfalusi, and
G Budai
September 1985,
Neuropharmacology,
I Sziráki, and
V Kardos, and
M Patthy, and
M Pátfalusi, and
G Budai
August 1998,
Neuroscience letters,
I Sziráki, and
V Kardos, and
M Patthy, and
M Pátfalusi, and
G Budai
April 2011,
Pharmacology, biochemistry, and behavior,
I Sziráki, and
V Kardos, and
M Patthy, and
M Pátfalusi, and
G Budai
December 2004,
Brain research,
I Sziráki, and
V Kardos, and
M Patthy, and
M Pátfalusi, and
G Budai
September 2017,
Scientific reports,
I Sziráki, and
V Kardos, and
M Patthy, and
M Pátfalusi, and
G Budai
January 2009,
Neuroscience research,
